AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35038165 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine
Number of subjects: 51
Study 35038165 — intervention group
Group type: COMPARATOR
Intervention: Sham subcutaneous injection of normal saline
Number of subjects: 51
Study 34127273 — intervention group
Group type: COMPARATOR
Intervention: Continued treatment with AChEI medications (sham-taper group)
Number of subjects: 62
Study 34127273 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment discontinuation via tapering (real-taper group)
Number of subjects: 62
Study 34127273 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment arms (sham-taper and real-taper)
Number of subjects: 62
Study 34127273 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver's mood
Number of subjects: 62
Study 32872476 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with CDI recurrence (n=77)
Number of subjects: 151
Study 32872476 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=74)
Number of subjects: 151
Study 36246996 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative intravenous amiodarone infusion
Number of subjects: 182
Study 36246996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 33742159 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking Chinese green tea (GT group)
Number of subjects: 80
Study 33742159 — intervention group
Group type: COMPARATOR
Intervention: Potable water (PW group)
Number of subjects: 80
Study 33980309 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (intervention group)
Number of subjects: 63
Study 33980309 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 63
Study 32386761 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1209
Study 32386761 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 1209
Study 34404828 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 27
Study 34404828 — intervention group
Group type: COMPARATOR
Intervention: Multiple daily injections (MDI)
Number of subjects: 27
Study 32453383 — intervention group
Group type: EXPERIMENTAL
Intervention: Academic detailing
Number of subjects: 5363
Study 32453383 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 5363
Study 35245262 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver educational program consisting of eight sessions (three educational sessions on COPD, two on coping strategies, three peer support sessions).
Number of subjects: 92
Study 35245262 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver educational program.
Number of subjects: 92
Study 34184991 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital cognitive behavioral therapy
Number of subjects: 45
Study 32886421 — intervention group
Group type: EXPERIMENTAL
Intervention: Geriatric interventions
Number of subjects: 0
Study 32886421 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 0
Study 33710942 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced active choice invitation letter
Number of subjects: 8349
Study 33710942 — intervention group
Group type: COMPARATOR
Intervention: Standard opt-in invitation letter (control condition)
Number of subjects: 8349
Study 32889703 — intervention group
Group type: EXPERIMENTAL
Intervention: ACDC intervention (14-week CBT-based group course)
Number of subjects: 228
Study 32889703 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC) control condition
Number of subjects: 228
Study 32889703 — intervention group
Group type: EXPERIMENTAL
Intervention: ACDC intervention
Number of subjects: 228
Study 34546226 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D digital photography
Number of subjects: 15
Study 34546226 — intervention group
Group type: EXPERIMENTAL
Intervention: Bellus3D
Number of subjects: 15
Study 34546226 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D facial scanners
Number of subjects: 15
Study 34546226 — intervention group
Group type: COMPARATOR
Intervention: Intraoral scans
Number of subjects: 15
Study 34600123 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery (total knee replacement)
Number of subjects: 207
Study 34600123 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative PTSD symptoms
Number of subjects: 207
Study 34600123 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 207
Study 34600123 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical claims filed before surgery
Number of subjects: 207
Study 33054695 — intervention group
Group type: EXPERIMENTAL
Intervention: Overnight fasting
Number of subjects: 21
Study 33054695 — intervention group
Group type: COMPARATOR
Intervention: Breakfast containing 20% of the total recommended daily calories
Number of subjects: 21
Study 34293304 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide 2·0 mg
Number of subjects: 961
Study 34293304 — intervention group
Group type: COMPARATOR
Intervention: Semaglutide 1·0 mg
Number of subjects: 961
Study 32727618 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Stepped Alcohol Treatment (ISAT)
Number of subjects: 93
Study 32727618 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 93
Study 33170353 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printed models of plates applied to the humerus
Number of subjects: 120
Study 33170353 — intervention group
Group type: EXPERIMENTAL
Intervention: Three different plates applied to the 3D models
Number of subjects: 120
Study 33765335 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamycin (GO) 6 mg/m2 added to standard chemotherapy
Number of subjects: 254
Study 33765335 — intervention group
Group type: COMPARATOR
Intervention: Standard chemotherapy alone
Number of subjects: 254
Study 32757060 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants who listened to their favourite music (n = 20) while watching the video.
Number of subjects: 80
Study 32757060 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre‐selected classical music excerpts varying in valence and arousal (happy, peaceful, agitated, sad) (n = 40) while watching the video.
Number of subjects: 80
Study 32757060 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 20) who watched the video without music.
Number of subjects: 80
Study 35341443 — intervention group
Group type: EXPERIMENTAL
Intervention: Online physiotherapy program
Number of subjects: 0
Study 35341443 — intervention group
Group type: COMPARATOR
Intervention: Active comparator (paper-based exercise program)
Number of subjects: 0
Study 33530248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic dehydrogenase-lymphocyte ratio (LLR) >345
Number of subjects: 145
Study 33530248 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic dehydrogenase levels
Number of subjects: 145
Study 33530248 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination scores including LLR
Number of subjects: 145
Study 33530248 — intervention group
Group type: EXPERIMENTAL
Intervention: LLR in validation cohort
Number of subjects: 145
Study 33530248 — intervention group
Group type: EXPERIMENTAL
Intervention: C-reactive protein, DIC score ≥2
Number of subjects: 145
Study 35805505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling dual-task intervention (cycling combined with a cognitive task)
Number of subjects: 0
Study 35805505 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 34423619 — intervention group
Group type: EXPERIMENTAL
Intervention: Adductor canal block combined with transcutaneous electrical acupoint stimulation (TEAS+ACB)
Number of subjects: 84
Study 34423619 — intervention group
Group type: COMPARATOR
Intervention: Adductor canal block (ACB)
Number of subjects: 84
Study 34081489 — intervention group
Group type: EXPERIMENTAL
Intervention: Active alcohol (target 0.08% breath alcohol content) and active cannabis (12.5% THC)
Number of subjects: 28
Study 34081489 — intervention group
Group type: COMPARATOR
Intervention: Placebo alcohol and placebo cannabis
Number of subjects: 28
Study 34081489 — intervention group
Group type: EXPERIMENTAL
Intervention: Active alcohol and placebo cannabis
Number of subjects: 28
Study 34081489 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo alcohol and active cannabis
Number of subjects: 28
Study 34081489 — intervention group
Group type: EXPERIMENTAL
Intervention: Active alcohol and active cannabis
Number of subjects: 28
Study 32895197 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital positioning guide plate
Number of subjects: 30
Study 32895197 — intervention group
Group type: COMPARATOR
Intervention: Control group (no guide plate)
Number of subjects: 30
Study 35288386 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET) combined with leucine and vitamin D-enriched whey protein-based oral nutritional supplement (2 times per day) for 13 weeks plus usual care
Number of subjects: 200
Study 35288386 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study 32859702 — intervention group
Group type: EXPERIMENTAL
Intervention: SSTR-RADS 1.0 scoring by 4 masked readers
Number of subjects: 51
Study 32859702 — intervention group
Group type: COMPARATOR
Intervention: SSTR-RADS 1.0 scoring by inexperienced readers
Number of subjects: 51
Study 33181371 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice-activated digital recording devices
Number of subjects: 20
Study 32265425 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting balloon (PEB)
Number of subjects: 222
Study 32265425 — intervention group
Group type: COMPARATOR
Intervention: Regular balloon angioplasty (BA)
Number of subjects: 222
Study 35291004 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rifampicin (30 mg/kg) and ethambutol (R30HZE, Arm 1)
Number of subjects: 37
Study 35291004 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose rifampicin and levofloxacin (R30HZL, Arm 2)
Number of subjects: 37
Study 35291004 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose rifampicin and ethambutol (R15HZE, Arm 3)
Number of subjects: 37
Study 34824344 — intervention group
Group type: EXPERIMENTAL
Intervention: SAR341402 insulin aspart
Number of subjects: 40
Study 34824344 — intervention group
Group type: COMPARATOR
Intervention: NovoRapid
Number of subjects: 40
Study 33619183 — intervention group
Group type: EXPERIMENTAL
Intervention: WASH intervention arm (comprehensive water improvement and hygiene education programme)
Number of subjects: 40
Study 33619183 — intervention group
Group type: COMPARATOR
Intervention: Delayed WASH arm (control group)
Number of subjects: 40
Study 33619183 — intervention group
Group type: EXPERIMENTAL
Intervention: WASH intervention arm
Number of subjects: 40
Study 32249950 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical stimulation of denervated muscle (ESDM)
Number of subjects: 38
Study 32249950 — intervention group
Group type: COMPARATOR
Intervention: Sham electrical stimulation
Number of subjects: 38
Study 32313928 — intervention group
Group type: EXPERIMENTAL
Intervention: HB-101 (low, medium, or high dose)
Number of subjects: 54
Study 32313928 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 32719875 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video
Number of subjects: 22
Study 32164762 — intervention group
Group type: EXPERIMENTAL
Intervention: Peficitinib (100 mg, or 50 mg for patients transferring from RAJ1), administered orally once daily
Number of subjects: 843
Study 35843714 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity treadmill aerobic exercise for four weeks
Number of subjects: 22
Study 35843714 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aerobic exercise)
Number of subjects: 22
Study 32811171 — intervention group
Group type: EXPERIMENTAL
Intervention: Improving Parents As Communication Teachers
Number of subjects: 97
Study 32811171 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 97
Study 36450211 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Walking Group (FWG)
Number of subjects: 76
Study 36450211 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Walking Group (MWG)
Number of subjects: 76
Study 36450211 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow Walking Group (SWG)
Number of subjects: 76
Study 36450211 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CON)
Number of subjects: 76
Study 34155812 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 100
Study 35075049 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagen membrane covering over BFP (Group II)
Number of subjects: 30
Study 35075049 — intervention group
Group type: COMPARATOR
Intervention: BFP alone (Group I)
Number of subjects: 30
Study 33370847 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivastar Silver Diammine Fluoride (SDF)
Number of subjects: 0
Study 33370847 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilised aqueous silver fluoride solution (AgF)
Number of subjects: 0
Study 33370847 — intervention group
Group type: COMPARATOR
Intervention: Rivastar Silver Diammine Fluoride (SDF) with Potassium Iodide (KI)
Number of subjects: 0
Study 33370847 — intervention group
Group type: COMPARATOR
Intervention: Stabilised aqueous silver fluoride solution (AgF) with Potassium Iodide (KI)
Number of subjects: 0
Study 33493023 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g of hemp protein (hemp40)
Number of subjects: 43
Study 33493023 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of hemp protein (hemp20)
Number of subjects: 43
Study 33493023 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 g of soybean protein (soy40)
Number of subjects: 43
Study 33493023 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 g of soybean protein (soy20)
Number of subjects: 43
Study 33493023 — intervention group
Group type: COMPARATOR
Intervention: Carbohydrate control
Number of subjects: 43
Study 32352008 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual Dynamic Activation (MDA)
Number of subjects: 65
Study 32352008 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic Irrigation (SI)
Number of subjects: 65
Study 32352008 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Ultrasonic Irrigation (PUI)
Number of subjects: 65
Study 32352008 — intervention group
Group type: COMPARATOR
Intervention: Conventional Needle Irrigation (CI)
Number of subjects: 65
Study 35577966 — intervention group
Group type: EXPERIMENTAL
Intervention: E-cigarettes
Number of subjects: 1140
Study 35577966 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patches
Number of subjects: 1140
Study 34195577 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (25 mg orally twice daily, reduced to once daily if eGFR was reduced)
Number of subjects: 117
Study 34195577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 34195577 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 117
Study 32862694 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 9326
Study 32862694 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 9326
Study 32862694 — intervention group
Group type: EXPERIMENTAL
Intervention: PRECISE‐DAPT score
Number of subjects: 9326
Study 32862694 — intervention group
Group type: EXPERIMENTAL
Intervention: PARIS score
Number of subjects: 9326
Study 32862694 — intervention group
Group type: EXPERIMENTAL
Intervention: DAPT (bleeding component) score
Number of subjects: 9326
Study 35180719 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical imiquimod (6.25 mg 3 times weekly for 8 to 16 weeks)
Number of subjects: 0
Study 35180719 — intervention group
Group type: COMPARATOR
Intervention: LLETZ (Large Loop Excision of the Transformation Zone)
Number of subjects: 0
Study 35180719 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical imiquimod
Number of subjects: 0
Study 35180719 — intervention group
Group type: COMPARATOR
Intervention: LLETZ
Number of subjects: 0
Study 33004392 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive voriconazole genotyping
Number of subjects: 146
Study 33004392 — intervention group
Group type: COMPARATOR
Intervention: Routine practice (control)
Number of subjects: 146
Study 36434797 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary vein isolation (PVI) alone
Number of subjects: 0
Study 36434797 — intervention group
Group type: EXPERIMENTAL
Intervention: Marshall-PLAN
Number of subjects: 0
Study 36434797 — intervention group
Group type: COMPARATOR
Intervention: PVI only (for patients with SR maintained for ≥4 weeks after EC)
Number of subjects: 0
Study 33651671 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab (1000 mg, two infusions administered two weeks apart)
Number of subjects: 57
Study 33651671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 33651671 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 57
Study 32739962 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB) 266 mg plus bupivacaine HCl 50 mg
Number of subjects: 186
Study 32739962 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine HCl 50 mg alone
Number of subjects: 186
Study 32739962 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (LB) plus bupivacaine HCl
Number of subjects: 186
Study 32739962 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine HCl alone
Number of subjects: 186
Study 36078628 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid (HA)
Number of subjects: 60
Study 36078628 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 60
Study 36078628 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound (US) + Isometric
Number of subjects: 60
Study 36078628 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Treatment (DN + HA)
Number of subjects: 60
Study 33446506 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-cm 22G long peripheral catheter (LPC)
Number of subjects: 72
Study 33446506 — intervention group
Group type: COMPARATOR
Intervention: 2.5-cm 22G peripheral intravenous catheter (PIVC)
Number of subjects: 72
Study 32074248 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral access
Number of subjects: 0
Study 32074248 — intervention group
Group type: COMPARATOR
Intervention: Radial access
Number of subjects: 0
Study 35754105 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mA cathodal tDCS over the left dorsolateral prefrontal cortex (dlPFC)
Number of subjects: 27
Study 35754105 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 27
Study 32493115 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose heparin
Number of subjects: 30
Study 32493115 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose heparin
Number of subjects: 30
Study 35236778 — intervention group
Group type: EXPERIMENTAL
Intervention: Postbiotic lozenge
Number of subjects: 75
Study 35236778 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-killed probiotic lozenge
Number of subjects: 75
Study 35236778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 32366578 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0
Study 32366578 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34587302 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir amibufenamide (TMF) 25 mg
Number of subjects: 1002
Study 34587302 — intervention group
Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF) 300 mg
Number of subjects: 1002
Study 33593477 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI group (sufentanil reduction if PPI<3, n=32)
Number of subjects: 57
Study 33593477 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard anesthesia, n=25)
Number of subjects: 57
Study 33593477 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI group
Number of subjects: 57
Study 35311721 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation guided by a telerehabilitation App (AppG)
Number of subjects: 49
Study 35311721 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control Group - CG)
Number of subjects: 49
Study 32365870 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week physical literacy intervention
Number of subjects: 90
Study 32365870 — intervention group
Group type: COMPARATOR
Intervention: Usual afterschool programming (Control)
Number of subjects: 90
Study 32365870 — intervention group
Group type: EXPERIMENTAL
Intervention: Program leaders' training
Number of subjects: 90
Study 35840273 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic lighting system in isolation rooms (experimental group)
Number of subjects: 148
Study 35840273 — intervention group
Group type: COMPARATOR
Intervention: Standard ICU lighting system (control group)
Number of subjects: 148
Study 34919250 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-Inositol (myo-Ins)
Number of subjects: 0
Study 34919250 — intervention group
Group type: EXPERIMENTAL
Intervention: Myo-Inositol (myo-Ins) plus Oral Contraceptive Pills (OCP)
Number of subjects: 0
Study 34919250 — intervention group
Group type: COMPARATOR
Intervention: Oral Contraceptive Pills (OCP)
Number of subjects: 0
Study 36153239 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal retainer
Number of subjects: 48
Study 36153239 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass Fiber Reinforced Composite (GFRC)
Number of subjects: 48
Study 36153239 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene Fiber Reinforced Composite (PFRC)
Number of subjects: 48
Study 33249632 — intervention group
Group type: EXPERIMENTAL
Intervention: BREATHE (shared decision-making intervention)
Number of subjects: 80
Study 33249632 — intervention group
Group type: COMPARATOR
Intervention: Dose-matched attention control
Number of subjects: 80
Study 33249632 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BREATHE and control)
Number of subjects: 80
Study 34514929 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept weekly (n=34)
Number of subjects: 66
Study 34514929 — intervention group
Group type: COMPARATOR
Intervention: Etanercept every other week (EOW) (n=32)
Number of subjects: 66
Study 34514929 — intervention group
Group type: EXPERIMENTAL
Intervention: Re-escalation to etanercept weekly
Number of subjects: 66
Study 35130256 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide plus Salbutamol
Number of subjects: 100